Press Releases

The laboratory builds upon City of Hope’s legacy of stem cell innovations, including its leading bone marrow/stem cell transplant program and cancer immunotherapy research

LOS ANGELES--(BUSINESS WIRE)-- City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its Duarte,... (continue reading...)

WASHINGTON, May 20, 2024 /PRNewswire/ -- The Coalition for Fair Trade in Shopping Bags (the "Coalition") applauds the final determinations announced today by the United States Department of Commerce ("Commerce") that imports of paper shopping bags into the United States from Cambodia, China, Colombia, India, Malaysia, Portugal, Taiwan, and Vietnam are being sold at less than fair value (commonly termed "dumping") and that imports from China and India also are being... (continue reading...)

Secure Path Cybersecurity and Compliance Services joins CompassMSP’s leading offerings, making IT environments even more stable and secure.

WEST HARTFORD, Conn.--(BUSINESS WIRE)-- CompassMSP, a leader in proactive managed IT solutions, today unveiled a new logo and web design that exemplifies its commitment to providing customers peace of mind via managed IT and cybersecurity. The new look and web site reflect the company’s leadership position and expanding... (continue reading...)

NEW YORK, May 20, 2024 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Exscientia p.l.c (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the “Class Period”), of the important June 25, 2024 lead plaintiff deadline.

SO WHAT: If you purchased Exscientia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or... (continue reading...)

MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2024, and provided a company update.

“As we work towards upcoming SAB-142... (continue reading...)